Provided by Tiger Trade Technology Pte. Ltd.

Tiziana Life Sciences PLC

1.43
-0.0500-3.38%
Volume:62.66K
Turnover:90.40K
Market Cap:181.61M
PE:-12.51
High:1.49
Open:1.49
Low:1.42
Close:1.48
52wk High:2.60
52wk Low:0.6703
Shares:127.00M
Float Shares:68.78M
Volume Ratio:0.29
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1143
EPS(LYR):-0.1112
ROE:-232.31%
ROA:-83.78%
PB:19.74
PE(LYR):-12.86

Loading ...

Tiziana Life Sciences announces publication of intranasal foralumab results

TIPRANKS
·
Jan 21

Tiziana Life Sciences Publishes Positive Clinical Results for Intranasal Foralumab in Progressive MS

Reuters
·
Jan 21

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

THOMSON REUTERS
·
Jan 21

Tiziana Life Sciences Launches Registered Direct Offering With Attached Warrants

Reuters
·
Jan 16

Press Release: Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Dow Jones
·
Jan 16

Tiziana Life Sciences to Present Intranasal Foralumab at Neuroscience Innovation Forum

Reuters
·
Jan 09

Tiziana Life Sciences Executive Chairman Gabriele Cerrone Acquires 97,687 Shares

Reuters
·
Dec 20, 2025

Tiziana Life Sciences Publishes AGM Presentation

Reuters
·
Dec 18, 2025

Tiziana Life Sciences Rings Nasdaq Closing Bell

Reuters
·
Dec 17, 2025

Tiziana Life Sciences Doses First Patient in Phase 2 Trial of Intranasal Foralumab for Early Alzheimer’s Disease

Reuters
·
Dec 17, 2025

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

THOMSON REUTERS
·
Dec 17, 2025

Tiziana Life Sciences CEO Increases Stake With Share Purchase

MT Newswires Live
·
Dec 16, 2025

Tiziana Life Sciences CEO Purchases 163,400 Shares in Open Market

Reuters
·
Dec 16, 2025

Tiziana Life Sciences Falls on Withdrawn Public Offering

Dow Jones
·
Dec 15, 2025

Tiziana Life Sciences Withdraws Proposed Public Offering

MT Newswires Live
·
Dec 15, 2025

BRIEF-Tiziana Life Sciences Announces Withdrawal Of Proposed Public Offering

Reuters
·
Dec 15, 2025

Tiziana Life Sciences: Withdrawal of Proposed Public Offering of Common Shares Due to Market Conditions

THOMSON REUTERS
·
Dec 15, 2025

Tiziana Life Sciences Launches Phase 2 Trial of Intranasal Foralumab for Early Alzheimer’s Disease

Reuters
·
Dec 13, 2025

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

THOMSON REUTERS
·
Dec 13, 2025

Tiziana Life Sciences to Spin Out IL-6 Asset into Separate Public Company

Reuters
·
Dec 02, 2025